Marimastat

Routes of
administrationBy mouth

ATC code

• None

Legal status

• Development terminated?

CAS Number

• 154039-60-8 ^Y

Marimastat

Clinical data
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	Development terminated?
Identifiers
IUPAC name N-[2,2-Dimethyl-1-(methylcarbamoyl)propyl]-2-[hydroxy-(hydroxycarbamoyl)methyl]-4- methyl-pentanamide
CAS Number	154039-60-8 Y
PubChem CID	119031
IUPHAR/BPS	5220
DrugBank	DB00786 N
ChemSpider	106358 N
UNII	D5EQV23TDS
ChEMBL	ChEMBL279785 N
PDB ligand	097 (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID20165524
Chemical and physical data
Formula	C15H29N3O5
Molar mass	331.413 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C
InChI InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1 N Key:OCSMOTCMPXTDND-OUAUKWLOSA-N N
NY (what is this?)  (verify)

Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.^[1][2]

Marimastat performed poorly in clinical trials,^[3] and development was terminated.^{[citation needed]} This may be, however, a result of targeting cancer at too late of a stage. This is supported by the fact that MMP inhibitors have more recently been shown in animal models to be more effective in earlier stages of cancers. (Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808–812. Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., and Hanahan, D. (1999)).